Taysha Gene Therapies, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
TSHA$4.33+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
Condensed Consolidated Balance Sheets
| September 30,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $297,344 | $139,036 |
| Restricted cash | 449 | 449 |
| Prepaid expenses and other current assets | 2,158 | 2,645 |
| Total current assets | 299,951 | 142,130 |
| Restricted cash | 2,151 | 2,151 |
| Property, plant and equipment, net | 6,805 | 7,485 |
| Operating lease right-of-use assets | 7,463 | 8,381 |
| Other non-current assets | 184 | 217 |
| Total assets | $316,554 | $160,364 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $5,438 | $3,592 |
| Accrued expenses and other current liabilities | 17,708 | 12,862 |
| Deferred revenue | 5,485 | 9,773 |
| Total current liabilities | 28,631 | 26,227 |
| Term loan, net | 50,852 | 43,942 |
| Operating lease liability, net of current portion | 16,506 | 17,361 |
| Other non-current liabilities | 1,576 | 1,309 |
| Total liabilities | 97,565 | 88,839 |
| Stockholders' equity | ||
| Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 273,915,373 issued and outstanding as of September 30, 2025 and 400,000,000 shares authorized and 204,943,306 issued and outstanding as of December 31, 2024 | 3 | 2 |
| Additional paid-in capital | 903,578 | 677,859 |
| Accumulated other comprehensive loss | (1,143) | (4,031) |
| Accumulated deficit | (683,449) | (602,305) |
| Total stockholders’ equity | 218,989 | 71,525 |
| Total liabilities and stockholders' equity | $316,554 | $160,364 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.